Roles of herparan sulfate proteoglycan modulation in upper gastrointestinal and pancreatic cancers.

Roles of herparan sulfate proteoglycan modulation in upper gastrointestinal and pancreatic cancers. - HeSUGaPa

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00029543

Enrollment

Registered

2022-09-13

Start date

2022-06-21

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C25.9 C15.9

Interventions

Group 1: Characterisation of HSPG expression in tumor and healthy tissue

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 30 patients each with uppergastrointestinal or pancreatic cancer that have been treated in the general and visceral surgery at Klinikum Oldenburg within the last 5 years

Exclusion criteria

Exclusion criteria: Patients who are not able to give their consent

Design outcomes

Primary

Measure	Time frame
FFPE (tumor vs healthy tissue) samples from patients with upper gastrointestinal cancer or pancreatic cancer will be analyzed for HSPG metabolism using immunofluorescence microscopy, nanostring analysis, and WB.	—

Countries

Germany

Contacts

Public ContactMaximilian Bockhorn

Universitätsklinik für Allgemein- und Viszeralchirurgie, Klinikum Oldenburg

maximilian.bockhorn@uni-oldenburg.de0441 403-2254

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026